TNGX Tango Therapeutics Inc: Accounting Value per Share

Graphic logo of Tango Therapeutics, Inc. (TNGX)

This chart of Tango Therapeutics (TNGX) stock quotes on the GURU.Markets platform reflects disciplined R&D control and support from pharma behemoths, with the key metric standing at 6.05. The business is implementing automated systems for accelerated molecular analysis to optimize drug discovery. However, current geopolitical tensions and sanctions are hindering the transportation of biomaterials, complicating global clinical trials.

TNGX: Tango Pharma Net Asset Value per Share 07/04/2022 - 10/27/2026

tangotx.com - analytical breakdowns and key metrics (TNGX)

- price and consensus price forecast:
Stock Price Tango Pharma|TNGX - Analyst Target Range
- market capitalization data:
Market Valuation Tango Therapeutics, Inc.|TNGX - Business Value
- book capitalization data:
Net Assets per Single Share Tango Therapeutics|TNGX - Total Stockholders' Equity|Market Value to Book Value Ratio tangotx.com|TNGX - Total Business Assets
- debt and liquidity data:
Total Debt to Capital Tango Therapeutics|TNGX - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Tango Therapeutics, Inc.|TNGX - Company Cumulative Debt|Debt to Book Capitalization Ratio Tango Therapeutics, Inc.
Fundamental company valuation:TNGX - Tango Pharma
Flagship merchandise of Tango Therapeutics, Inc.

Book value per share determines the net assets of a company available to common shareholders after deducting all liabilities and preferred securities. For Tango Therapeutics (TNGX), this metric reflects a financial foundation independent of macroeconomic cycles and seasonality. By analyzing the dynamics of book value per share, an investor assesses the efficiency of capital management. Growth in this metric confirms the accumulation of resources required to conduct costly clinical trials. The stability of this indicator testifies to the high level of asset protection within the biotechnology business.

Competitor analysis for Tango Therapeutics

Book Value per Share IBRX|Immunocore Corp (IMCR) - Book Value of One Share|Accounting Value per Share Janux Therapeutics|RCUS (arcusbio.com) - Equity per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share IOVA|Net Assets per Single Share Immatics Corp IMTX|Equity per Share Xencor Inc. (XNCR)|Compass Therapeutics - Book Value per Share|replimune.com - Accounting Value per Share|LYEL (Lyell Immunopharma, Inc.) - Net Assets per Single Share|IPHA: Net Asset Value per Share|pyxisoncology.com (PYXS) - Net Assets per Single Share|CGEN (Compugen) - Net Assets per Single Share|Net Assets per Single Share IOBT (IO Biotech, Inc.)|Net Asset Value per Share sutrobio.com|INKT: Book Value per Share|Book Value of One Share werewolftx.com HOWL|IMMX: Accounting Value per Share|ALXO - Net Asset Value per Share|Accounting Value per Share Cue Biopharma, Inc. (CUE)|PDSB - Accounting Value of a Share|sonnetbio.com - Book Value per Share|MAIA (MAIA Biotech) - Net Assets per Share|Net Assets per Single Share LIMN|Accounting Value per Share LVTX|Net Assets per Single Share NXTC (NextCure, Inc.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx